Equillium Inc EQ:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 2:40 PM EDT
1.75quote price arrow down-0.04 (-2.25%)
Volume
65,635
52 week range
0.45 - 3.25
Loading...
  • Open1.76
  • Day High1.84
  • Day Low1.71
  • Prev Close1.79
  • 52 Week High3.25
  • 52 Week High Date02/26/24
  • 52 Week Low0.45
  • 52 Week Low Date11/13/23

Key Stats

  • Market Cap61.685M
  • Shares Out35.25M
  • 10 Day Average Volume0.10M
  • Dividend-
  • Dividend Yield-
  • Beta1.72
  • YTD % Change138.44

KEY STATS

  • Open1.76
  • Day High1.84
  • Day Low1.71
  • Prev Close1.79
  • 52 Week High3.25
  • 52 Week High Date02/26/24
  • 52 Week Low0.45
  • 52 Week Low Date11/13/23
  • Market Cap61.685M
  • Shares Out35.25M
  • 10 Day Average Volume0.10M
  • Dividend-
  • Dividend Yield-
  • Beta1.72
  • YTD % Change138.44

RATIOS/PROFITABILITY

  • EPS (TTM)-0.38
  • P/E (TTM)-4.55
  • Fwd P/E (NTM)-60.33
  • EBITDA (TTM)-14.396M
  • ROE (TTM)-48.92%
  • Revenue (TTM)36.084M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-36.96%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/09/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Equillium Inc

 

Profile

MORE
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine...
Daniel Bradbury
Executive Chairman of the Board
Bruce Steel
President, Chief Executive Officer, Director
Christine Zedelmayer
Chief Operating Officer, Senior Vice President
Address
2223 Avenida de La Playa Ste 105
La Jolla, CA
92037-3217
United States

Top Peers

SYMBOLLASTCHG%CHG
PRE
Prenetics Global Ltd
3.15UNCHUNCH
TKNO
Alpha Teknova Inc
2.09-0.02-0.95%
ACRS
Aclaris Therapeutics Inc
1.25+0.02+1.63%
AADI
Aadi Bioscience Inc
1.79-0.03-1.37%
PLX
Protalix Biotherapeutics Inc
1.13-0.02-1.74%